NasdaqCM:VKTXBiotechs
Viking Therapeutics (VKTX) Stock Still Looks Pricey With Pipeline Hopes Priced In
Viking Therapeutics has delivered a very large 463.7% return over the past five years, yet the stock currently screens as expensive on the valuation checks, which raises questions about how much optimism is already in the price.
Over five years, Viking Therapeutics has returned 463.7%, which signals investors have already paid up heavily for the growth story.
Expectations for future revenue and cash flow from Viking Therapeutics' pipeline can support a premium, although any delay in turning...